Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Acquired IPR&D costs In-Process Research And Development Expense In-Process Research And Development Expense Maximum Maximum [Member] Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Weighted average interest rate Debt, Weighted Average Interest Rate Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Adjustment to Compensation, Amount Adjustment to Compensation Amount Segment Reporting [Abstract] Segment Reporting [Abstract] Schedule of estimated aggregate amortization expense for each of the five succeeding years Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense [Table Text Block] B&L Trademark Trademarks [Member] Federal Funds Effective Rate and Overnight Bank Funding Rate Federal Funds Effective Rate And Overnight Bank Funding Rate [Member] Federal Funds Effective Rate And Overnight Bank Funding Rate Derivative Instrument [Axis] Derivative Instrument [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Senior Secured 10.00% Notes Due April 2032 Senior Secured 10.00% Notes Due April 2032 [Member] Senior Secured 10.00% Notes Due April 2032 Current period provisions SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Property, plant and equipment, net Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment Canadian Overnight Repo Rate Average Canadian Overnight Repo Rate Average [Member] Canadian Overnight Repo Rate Average Doctors Allergy Formula, LLC Litigation Doctors Allergy Formula, LLC Litigation [Member] Doctors Allergy Formula, LLC Litigation [Member] Payments of contingent consideration adjustments, including accretion Payment For Contingent Consideration Liability, Including Accretion, Operating Activities Payment For Contingent Consideration Liability, Including Accretion, Operating Activities Number of claims dismissed Loss Contingency, Claims Dismissed, Number The Anticipated Cabtreo Paragraph IV Proceedings The Anticipated Cabtreo Paragraph IV Proceedings [Member] The Anticipated Cabtreo Paragraph IV Proceedings Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Amortization of intangible assets Amortization of intangible assets Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period. Asset Acquisition [Axis] Asset Acquisition [Axis] Intangible assets, net Net Carrying Amount Intangible Asset, Excluding Goodwill, after Accumulated Amortization Frank Lee [Member] Frank Lee Collateral amount Debt Instrument, Collateral Amount Schedule of share-based awards Share-Based Payment Arrangement, Activity [Table Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Quality assurance Research And Development Expense, Quality Assurance Research And Development Expense, Quality Assurance Term Loan B Facility Due May 2027 Term Loan B Due May 2027 [Member] Term Loan B Due May 2027 Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Entity Address, City or Town Entity Address, City or Town Net fair value Net fair value Derivative, Fair Value, Net Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] 7.25% Senior Notes Due May 2029 Senior Notes, 7.25%, Due May 2029 [Member] Senior Notes 7.25 Percent Due May 2029 [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Other, net Other Income (Expense), Net Other Income (Expense), Net Product sales Product [Member] Net Carrying Amount Finite-lived intangible assets Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Other comprehensive (loss) income Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Aimee Lenar [Member] Aimee Lenar Number of groups of investors filing action Loss Contingency, Plaintiffs, Number Of Groups Of Investors Loss Contingency, Plaintiffs, Number Of Groups Of Investors Subsequent Event Type [Axis] Subsequent Event Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Other liabilities Business Combination, Recognized Liability Assumed, Other Liability, Current Schedule of segment revenues and profit Segment Reporting [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Deferred income taxes Deferred Income Tax Noncash Expense (Benefit) The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations. Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Document Period End Date Document Period End Date 9.00% Intermediate Holdco Senior Notes, Due January 2028 9.00% Intermediate Holdco Secured Notes due 2028 Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028 [Member] Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028 Fair value of reporting value, greater than its carrying value Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Principal amount Debt Instrument, Face Amount Other Other Long Term Debt [Member] Represents long-term debt obligations not elsewhere enumerated. Term Debt Instrument, Term Bausch + Lomb Bausch + Lomb Bausch + Lomb [Member] Bausch + Lomb SOFR, EUTIBOT and Term CORRA Secured Overnight Financing (SOFR) Rate, EURIBOR, And Canadian Overnight Repo Rate Average [Member] Secured Overnight Financing (SOFR) Rate, EURIBOR, And Canadian Overnight Repo Rate Average Remaining quarterly amortization payments Debt Instrument, Periodic Payment, Remaining Quarterly Amortization Debt Instrument, Periodic Payment, Remaining Quarterly Amortization Number of debt instruments Debt Instrument, Number Debt Instrument, Number Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Consolidation Items [Domain] Consolidation Items [Domain] BRITISH COLUMBIA BRITISH COLUMBIA Acquisition-related contingent consideration (Note 4) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Lumify Paragraph I V Proceedings Slayback ANDA Litigation Lumify Paragraph I V Proceedings Slayback ANDA Litigation [Member] Lumify Paragraph I V Proceedings Slayback ANDA Litigation Effective income tax rate reconciliation, tax settlement, amount Effective Income Tax Rate Reconciliation, Tax Settlement, Amount EARNINGS (LOSS) PER SHARE Earnings Per Share [Text Block] Earnings (loss) per share attributable to Bausch Health Companies Inc. Earnings Per Share [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Income taxes payable Accrued Income Taxes, Current Schedule of fair values of assets acquired and liabilities assumed Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block] Company Selected Measure Name Company Selected Measure Name Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Business Combination, Contingent Consideration, Type [Axis] Business Combination, Contingent Consideration, Type [Axis] Customer, Top Ten Products Customer, Top Ten Products [Member] Customer, Top Ten Products Schedule of foreign exchange contracts on the consolidated statements of operations and consolidated statements of cash flows Derivatives Not Designated as Hedging Instruments [Table Text Block] Commitment fee (as a percent) Line of Credit Facility, Commitment Fee Percentage Credit Facility [Domain] Credit Facility [Domain] Depreciation and amortization of intangible assets Depreciation, Depletion and Amortization, Nonproduction Cash Flows From Operating Activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Tax Year 2018 and 2019 Tax Year 2018 And 2019 [Member] Tax Year 2018 And 2019 Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Total identifiable net assets Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] First Lien Secured 11.00% Notes Due December 2025 First Lien Secured 11.00% Notes Due December 2025 [Member] First Lien Secured 11.00% Notes Due December 2025 Quarterly amortization payments Debt Instrument, Periodic Payment, Quarterly Amortization, Period One Debt Instrument, Periodic Payment, Quarterly Amortization, Period One Intangible assets Finite Lived and Indefinite Lived Intangible Assets [Line Items] -- None. No documentation exists for this element. -- Award Timing Predetermined Award Timing Predetermined [Flag] Harmac Medical products, Inc. Harmac Medical products, Inc. [Member] Harmac Medical products, Inc. Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Stay of approval, period Gain Contingency, Stay Of Approval, Period Gain Contingency, Stay Of Approval, Period Diluted effect of stock options and RSUs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Reporting unit, impairment test, long-term growth rate Reporting Unit, Impairment Test, Long-Term Growth Rate Reporting Unit, Impairment Test, Long-Term Growth Rate Schedule of effect of hedging instruments on financial statements Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block] Plan Name [Domain] Plan Name [Domain] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] TSR PSUs TSR Performance-Based Restricted Stock Units [Member] TSR Performance-Based Restricted Stock Units [Member] Total fair value of consideration transferred Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Norwich II Xifaxan Litigation Norwich II Xifaxan Litigation [Member] Norwich II Xifaxan Litigation Expiration Date Trading Arrangement Expiration Date 2030 Long-Term Debt, Maturity, Year Four Hedging Relationship [Axis] Hedging Relationship [Axis] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Total (deficit) equity Beginning Balance Ending Balance Accumulated other comprehensive loss Equity, Including Portion Attributable to Noncontrolling Interest Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Trade receivables Business Combination, Recognized Asset Acquired, Receivable, Current SOFR, EURIBOR, and SONIA Rate Secured Overnight Financing (SOFR) Rate, EURIBOR, And Sterling Overnight Index Average (SONIA) Rate [Member] Secured Overnight Financing (SOFR) Rate, EURIBOR, And Sterling Overnight Index Average (SONIA) Rate Cash Flows From Investing Activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Litigation Status [Axis] Litigation Status [Axis] Remaining unrecognized compensation expense related to non-vested awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Highly liquid investments, maturity period (or less) Highly Liquid Investments, Maturity Period Highly Liquid Investments, Maturity Period Segments [Domain] Segments [Domain] Pending Litigation, Agreed Stipulations of Dismissal Submitted Pending Litigation, Agreed Stipulations Of Dismissal Submitted [Member] Pending Litigation, Agreed Stipulations Of Dismissal Submitted FINANCING ARRANGEMENTS Debt Disclosure [Text Block] Secured leverage ratio (less than) Debt Instrument, Covenant Terms, Secured Leverage Ratio Debt Instrument, Covenant Terms, Secured Leverage Ratio Debt issuance costs, net Debt Issuance Costs, Net Variable rate, floor (as a percent) Debt Instrument, Variable Rate, Floor Debt Instrument, Variable Rate, Floor Business Combination [Table] Business Combination [Table] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Secured Notes Secured Debt [Member] Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Total expenses Costs and Expenses Thereafter Long-Term Debt, Maturity, after Year Five Disposition of property threshold Debt Instrument, Restrictive Covenant, Disposition Of Property, Threshold Debt Instrument, Restrictive Covenant, Disposition Of Property, Threshold Stated interest rate on debt (as a percent) Debt Instrument, Interest Rate, Stated Percentage Total Bausch Health Companies Inc. shareholders’ deficit Equity, Attributable to Parent Assets Assets [Abstract] Product rights/patents Contractual Rights [Member] 5.25% Senior Notes Due January 2030 Senior Notes, 5.25%, Due January 2030 [Member] 5.25% Senior Notes Due January 2030 [Member] Nonrecurring adjustment Fair Value, Nonrecurring [Member] Insider Trading Policies and Procedures [Line Items] Term Loan B Facility Due 2030 Term Loan B Facility Due 2030 [Member] Term Loan B Facility Due 2030 Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Subsidiary, number of owned, parent (in shares) Subsidiary, Number Of Shares Owned, Parent Subsidiary, Number Of Shares Owned, Parent Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Term Loan B Due September 2028 Term Loan B Due September 2028 [Member] Term Loan B Due September 2028 Neurology Reporting Unit Neurology Reporting Unit [Member] Neurology Reporting Unit Sandoz Canada Inc. Sandoz Canada Inc. [Member] Sandoz Canada Inc. Performance-based RSUs Performance-Based RSUs Performance-Based Restricted Stock Units [Member] Performance-Based Restricted Stock Units Number of operating segments Number of Operating Segments Dilutive effect of potential common shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of changes in the carrying amount of goodwill Goodwill [Table Text Block] Entity Central Index Key Entity Central Index Key Additional paid-in capital Additional Paid in Capital, Common Stock Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Costs incurred Restructuring and Related Cost, Incurred Cost Income tax provision (benefit) on ordinary income (loss) Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Payments of accrued legal settlements Payments for Legal Settlements LEGAL PROCEEDINGS Legal Matters and Contingencies [Text Block] Foreign exchange and other Foreign Currency Transaction And Other Gain (Loss), Before Tax Foreign Currency Transaction And Other Gain (Loss), Before Tax Remainder of 2026 Long-Term Debt, Maturity, Remainder of Fiscal Year Cash settlement of share-based awards Share-Based Payment Arrangement, Cash Used to Settle Award Ownership [Axis] Ownership [Axis] 5.75% Senior Secured Notes due 2027 Senior Secured 5.75% Notes Due August 2027 [Member] Senior Secured 5.75% Notes Due August 2027 [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Designated as Hedging Instrument Designated as Hedging Instrument [Member] February 2027 Term Loan B Facility February 2027 Term Loan B Facility [Member] February 2027 Term Loan B Facility Dismissed for Failure to Comply Dismissed For Failure To Comply [Member] Dismissed For Failure To Comply Asset acquisition, recognized assets acquired Asset Acquisition, Recognized Assets Acquired Asset Acquisition, Recognized Assets Acquired Variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Other current assets Business Combination, Recognized Asset Acquired, Other Asset, Current Variable Rate [Domain] Variable Rate [Domain] Income Tax Examination [Line Items] Income Tax Examination [Line Items] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Income tax (benefit) provision associated with the filing of certain income tax returns Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount All Individuals All Individuals [Member] Reserve beginning balance Reserve ending balance Cooperative advertising credits included in rebates SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Weighted average service period over which compensation cost is expected to be recognized (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Annual amortization rate (as a percent) Debt Instrument, Annual Amortization Rate, Percentage Debt Instrument, Annual Amortization Rate, Percentage Non-current portion included in Other non-current liabilities Business Combination, Contingent Consideration, Liability, Noncurrent Statement [Line Items] Statement [Line Items] Total assets Assets 5.00% Senior Notes Due January 2028 Senior Notes, 5.00%, Due January 2028 [Member] 5.00% Senior Notes Due January 2028 [Member] Acquired IPR&D Acquired In Process Research And Development [Member] Acquired In Process Research And Development Price Appreciation Credit Price Appreciation Credit [Member] Price Appreciation Credit [Member] Operating Segment Operating Segments [Member] Weighted-average grant date fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value SHARE-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Reconciliation of contingent payment obligations measured on a recurring basis Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] RESTRUCTURING, INTEGRATION AND SEPARATION COSTS Restructuring And Related Activities And Initial Public Offering Costs Disclosure [Text Block] Restructuring And Related Activities And Initial Public Offering Costs Disclosure PEO PEO [Member] 2028 Long-Term Debt, Maturity, Year Two Other non-current liabilities Other Liabilities, Noncurrent Goodwill Balance at the beginning of the period Balance at the end of the period Goodwill Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Schedule of research and development Summary Of Research And Development Expense [Table Text Block] Summary Of Research And Development Expense [Table Text Block] Senior Secured 10.00% Notes Due 2032 Senior Secured 10.00% Notes Due 2032 [Member] Senior Secured 10.00% Notes Due 2032 Income tax provision (benefit) related to changes in uncertain tax positions Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Accumulated Deficit Retained Earnings [Member] Revolving Credit Facility Revolving Credit Facility [Member] Increase (Decrease) in Shareholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Common shares, outstanding (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Foreign currency translation adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share) Earnings Per Share, Diluted Acquisition-related contingent consideration Business Acquisition, Contingent Consideration Fair Value Disclosure Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares. Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Time-based RSUs, Performance-based RSUs and Stock Options Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member] Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member] Financial leases Secured Borrowing, Current Secured Borrowing, Current Litigation Case [Domain] Litigation Case [Domain] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table] Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table] Ownership [Domain] Ownership [Domain] Senior Secured Notes Due January 2031 Senior Secured Notes Due January 2031 [Member] Senior Secured Notes Due January 2031 Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Revenues Price appreciation credits Revenues Revenue from Contract with Customer, Excluding Assessed Tax Remaining borrowings Line of Credit Facility, Remaining Borrowing Capacity Salix Salix Salix Segment [Member] Salix Segment [Member] Asset, contingent consideration Asset Acquisition, Contingent Consideration, Range of Outcomes, Maximum, Amount Asset Acquisition, Contingent Consideration, Range of Outcomes, Maximum, Amount Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] 2022 Omnibus Incentive Plan 2022 Omnibus Incentive Plan [Member] 2022 Omnibus Incentive Plan Gross Carrying Amount Intangible Asset, Excluding Goodwill, before Accumulated Amortization Norwich I Xifaxan Litigation Norwich I Xifaxan Litigation [Member] Norwich I Xifaxan Litigation One Month Interest Period One Month Interest Period [Member] One Month Interest Period April 2025 Refinancing Transactions April 2025 Refinancing Transactions [Member] April 2025 Refinancing Transactions Schedule of long-term debt maturities Schedule of Maturities of Long-Term Debt [Table Text Block] ACCRUED AND OTHER CURRENT LIABILITIES Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Time-based RSUs Time Based RSU [Member] Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan. Adjustments to accrued legal settlements Gain (Loss) Related To Litigation Settlement, Gross Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds. Operating income (loss) Operating Income (Loss) Discounts and Allowances Reserve For Discounts And Allowances [Member] Reserve For Discounts And Allowances [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Income Tax Examination [Table] Income Tax, Examination [Table] Asset impairments Asset, Impairment Loss Anti-dilutive shares not included in the computation of diluted earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common shares, issued (in shares) Beginning Balance (in shares) Ending Balance (in shares) Common Stock, Shares, Issued Finished goods Inventory, Finished Goods, Gross Surgical Manufacturing Facility Surgical Manufacturing Facility [Member] Surgical Manufacturing Facility ACCUMULATED OTHER COMPREHENSIVE LOSS Comprehensive Income (Loss) Note [Text Block] Trade receivables Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Deferred tax liabilities, net Deferred Income Tax Liabilities, Net Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Gain (loss) related to changes in fair value Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Termination Date Trading Arrangement Termination Date Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Incentive stock plan, term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Unrecognized tax benefits related to interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Accrued and other current liabilities Accrued and other current liabilities Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Net gain on sale of assets Gain (Loss) on Disposition of Assets Loss contingency, patents allegedly infringed, number Loss Contingency, Patents Allegedly Infringed, Number Goodwill [Table] Goodwill [Table] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration 11.00% First Lien Secured Notes due in 2028 11.00% First Lien Secured Notes due in 2028 [Member] 11.00% First Lien Secured Notes due in 2028 Product rebates Accrued Product Rebate Current Represents the current portion of accrued product rebates. Consolidation Items [Axis] Consolidation Items [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Shibo Zhenmei Shibo Zhenmei [Member] Shibo Zhenmei Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Number of countries in which entity operates Number of Countries in which Entity Operates Gross Carrying Amount Intangible Asset, Finite-Lived, before Accumulated Amortization Accounts payable, accrued and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Change in the carrying amount of goodwill Goodwill [Roll Forward] Intangible Asset, Finite-Lived, Class [Domain] Intangible Asset, Finite-Lived, Class [Domain] Revolving Credit Facility, Maturing June 2026 Revolving Credit Facility, Maturing June 2026 [Member] Revolving Credit Facility, Maturing June 2026 Corporate brands Trade Names [Member] Schedule of components and classification of financial assets and liabilities measured at fair value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Award Type [Domain] Award Type [Domain] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] 2027 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One Common shares, authorized (in shares) Common Stock, Shares Authorized, Unlimited [Fixed List] QUEBEC QUEBEC Geographical [Axis] Geographical [Axis] Accretion for the time value of money Accretion For Time Value Of Money [Member] Accretion For Time Value Of Money [Member] Payments of acquisition-related contingent consideration Payment for Contingent Consideration Liability, Financing Activities Legal Entity [Axis] Legal Entity [Axis] Interest expense Interest expense Interest Expense, Debt Payments and credits SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Troubled Debt Restructuring, Debtor, Subsequent Periods, Contingent Payments, Name [Domain] Troubled Debt Restructuring, Debtor, Subsequent Periods, Contingent Payments, Name [Domain] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Non-NEOs Non-NEOs [Member] Reporting Unit [Domain] Reporting Unit [Domain] Cash consideration paid Payments to Acquire Businesses, Gross 2028 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two Allowance for Credit Losses Credit Loss, Financial Instrument [Policy Text Block] Product brands Product Brands [Member] Represents the rights to non-patented product brands. Schedule of long-term debt Schedule of Debt [Table Text Block] Customer [Domain] Customer [Domain] Schedule of inventories, net Schedule of Inventory, Current [Table Text Block] 2027 Long-Term Debt, Maturity, Year One Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Number of entities, exercised opt-out right, pursuing action Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action Raw materials Inventory, Raw Materials, Gross Statistical Measurement [Axis] Statistical Measurement [Axis] Award Type [Axis] Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Reduction of outstanding principal Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal Revolving Credit Facility Due May 2027 Revolving Credit Facility Due May 2027 [Member] Revolving Credit Facility Due May 2027 Gain excluded from assessment of hedge effectiveness Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Product and Service [Axis] Product and Service [Axis] Acquisition-related contingent consideration Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Shares Common Stock [Member] Non-current portion of financial leases Secured Borrowing, Noncurrent Secured Borrowing, Noncurrent Fair value adjustments due to changes in estimates of future payments Fair Value Adjustments, Changes In Estimates Of Future Payments [Member] Fair Value Adjustments, Changes In Estimates Of Future Payments [Member] Adjusted EBITDA PSUs Adjusted EBITDA Performance-Based Restricted Stock Units [Member] Adjusted EBITDA Performance-Based Restricted Stock Units Asset acquisition, recognized liabilities assumed Asset Acquisition, Recognized Liabilities Assumed Asset Acquisition, Recognized Liabilities Assumed 14.00% Second Lien Senior Notes, Due October 2030 Senior Secured 14.00% Notes, Second Lien, Due October 2030 [Member] Senior Secured 14.00% Notes, Second Lien, Due October 2030 Other Bausch + Lomb Acquisitions Other Bausch + Lomb Acquisitions [Member] Other Bausch + Lomb Acquisitions Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign exchange and other Goodwill, Foreign Currency Translation, Gain (Loss) Total liabilities and equity Liabilities and Equity Stock options Stock options Share-Based Payment Arrangement, Option [Member] Noncontrolling interest Equity, Attributable to Noncontrolling Interest Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Restructuring charges Restructuring Charges Tabular List, Table Tabular List [Table Text Block] Acquisition of intangible assets and other assets Payments to Acquire Intangible Assets Debt Instrument, Period [Domain] Debt Instrument, Period [Domain] Debt Instrument, Period 2025 Credit Agreement 2025 Credit Agreement [Member] 2025 Credit Agreement 2029 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three Dividend and distribution threshold Debt Instrument, Restrictive Covenant, Dividends Or Distributions, Threshold Debt Instrument, Restrictive Covenant, Dividends Or Distributions, Threshold Remainder of 2026 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Remainder of Fiscal Year Other expense (income), net Other expense (income), net Other expense (income), net Other Operating Income (Expense), Net Name Awards Close in Time to MNPI Disclosures, Individual Name Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Business Combination, Contingent Consideration, Type [Domain] Business Combination, Contingent Consideration, Type [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Cost-rationalization and integration initiatives Restructuring Cost and Reserve [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Payments to acquire productive assets Payments to Acquire Productive Assets Extinguishment of debt, amount Extinguishment of Debt, Amount Hedging Designation [Axis] Hedging Designation [Axis] Credit Facility [Axis] Credit Facility [Axis] Restructuring, Integration and Separation Costs Separation And Initial Public Offering Costs [Member] Separation And Initial Public Offering Costs Name Measure Name Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Long-term debt, net of unamortized debt discount Debt Instrument [Line Items] Debt Instrument [Line Items] Senior Notes, 9.25%, Due August 2025 Senior Notes, 9.25%, Due August 2025 [Member] Senior Notes, 9.25%, Due August 2025 Additional Paid-In Capital Additional Paid-in Capital [Member] Indefinite-lived Intangible Assets [Axis] Intangible Asset, Indefinite-Lived, Class [Axis] Goodwill, impairment loss Impairment Goodwill, Impairment Loss Name Trading Arrangement, Individual Name 5.50% Senior Secured Notes due 2025 Senior Secured 5.50% Notes Due November 2025 [Member] Senior Secured 5.50% Notes Due November 2025 [Member] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalent Company Selected Measure Amount Company Selected Measure Amount Tax Period [Domain] Tax Period [Domain] Total Inventories Inventory, Gross SOFR Rate Secured Overnight Financing Rate (SOFR) [Member] Common shares issued under share-based compensation plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Portion of unrecognized tax benefits, if recognized, would reduce the company's effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate 2031 Long-Term Debt, Maturity, Year Five Non-PEO NEO Non-PEO NEO [Member] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Foreign exchange and other Gain (Loss), Foreign Currency Transaction, before Tax OTHER EXPENSE (INCOME), NET Other Income and Other Expense Disclosure [Text Block] Applicable Rate Applicable Rate [Member] Applicable Rate Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues Cost of goods sold and Cost of other revenues Cost of Product and Service Sold SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Award Timing Method Award Timing Method [Text Block] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Other revenues Product and Service, Other [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Net income (loss) attributable to Bausch Health Companies Inc. Net income (loss) attributable to Bausch Health Companies Inc. Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Location, Statement of Financial Position, Balance [Axis] Location, Statement of Financial Position, Balance [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Schedule of the components of accumulated other comprehensive loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Debt instrument, premium Debt Instrument, Unamortized Premium Sale of financial assets Transfer of Financial Assets Accounted for as Sales, Cash Proceeds Received for Assets Derecognized, Amount Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments (as a percent) Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments. Goodwill reclassified to assets held for sale Goodwill, Transfers Alternate Base Rate Alternate Base Rate [Member] Alternate Base Rate 2032 Senior Secured Notes 2032 Senior Secured Notes [Member] 2032 Senior Secured Notes Number of suits filed Loss Contingency, New Claims Filed, Number Gain (loss) recognized in Other comprehensive income (loss) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Revenues Revenues Net [Member] Aggregate net revenues during the period in the normal course of business. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Revenues Revenues [Abstract] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Weighted-average common shares Weighted Average Number of Shares Outstanding, Diluted [Abstract] New Jersey NEW JERSEY Statistical Measurement [Domain] Statistical Measurement [Domain] Aimee Lenar, Trading Arrangement, 50% Of Vested And Settled Restricted Stock Units [Member] Aimee Lenar, Trading Arrangement, 50% Of Vested And Settled Restricted Stock Units Alternate maturity, threshold, aggregate principal amount Debt Instrument, Alternate Maturity, Threshold, Aggregate Principal Amount, In Excess Of Debt Instrument, Alternate Maturity, Threshold, Aggregate Principal Amount, In Excess Of Document Fiscal Year Focus Document Fiscal Year Focus Acquisition-related transaction costs Business Combination, Acquisition-Related Cost, Expense Income tax provision (benefit) for discrete items Effective Income Tax Rate Reconciliation, Discrete Items, Amount Effective Income Tax Rate Reconciliation, Discrete Items, Amount Customer [Axis] Customer [Axis] Whitecap Biosciences Acquisition Whitecap Biosciences Acquisition [Member] Whitecap Biosciences Acquisition Common shares, no par value, unlimited shares authorized, 373,901,440 and 370,531,987 issued and outstanding at June 30, 2026 and December 31, 2025, respectively Common Stock, Value, Issued Payments of employee withholding taxes related to share-based awards Payment, Tax Withholding, Share-Based Payment Arrangement Canadian Securities Litigation Canadian Securities Litigation [Member] Canadian Securities Litigation Line of Credit Line of Credit [Member] Restatement Determination Date Restatement Determination Date Senior Secured 4.875% Notes Due December 2028 Senior Secured 4.875% Notes Due December 2028 [Member] Senior Secured 4.875% Notes Due December 2028 Acquisition-related contingent consideration Business Combination, Contingent Consideration, Noncurrent Liability Business Combination, Contingent Consideration, Noncurrent Liability Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Indefinite-lived intangible assets: Intangible Asset, Excluding Goodwill, Indefinite-Lived [Abstract] Amendment Flag Amendment Flag Goodwill [Line Items] Goodwill [Line Items] Current liabilities: Liabilities, Current [Abstract] Provision for expected credit losses Accounts Receivable, Credit Loss Expense (Reversal) Contractual interest paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Loss Contingencies [Table] Loss Contingencies [Table] Troubled Debt Restructuring, Debtor, Subsequent Periods [Axis] Troubled Debt Restructuring, Debtor, Subsequent Periods [Axis] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Organic Revenue Growth PSUs Organic Revenue Growth Performance-Based Restricted Stock Units [Member] Organic Revenue Growth Performance-Based Restricted Stock Units PEO Total Compensation Amount PEO Total Compensation Amount Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Assets: Assets, Fair Value Disclosure [Abstract] Aggregate notional amounts Derivative, Notional Amount Basic weighted-average common shares (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Accumulated goodwill impairment charges Goodwill, Impaired, Accumulated Impairment Loss Loss Contingencies [Line Items] Loss Contingencies [Line Items] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Extinguishment of Debt [Table] Extinguishment of Debt [Table] Troubled Debt Restructuring, Debtor, Type [Axis] Troubled Debt Restructuring, Debtor, Type [Axis] Troubled Debt Restructuring, Debtor, Type Loss related to settlements Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss) Related To Settlement Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss) Related To Settlement SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Asset acquisition, consideration transferred Asset Acquisition, Consideration Transferred Pending Litigation Pending Litigation [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Accumulated Amortization and Impairments Intangible Asset, Finite-Lived, Accumulated Amortization Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Current portion of long-term debt Less: Current portion of long-term debt and other Long-Term Debt, Current Maturities Salix Reporting Unit Salix Reporting Unit [Member] Salix Reporting Unit Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] New Accounting Standards and Recently Issued Accounting Standards, Not Adopted New Accounting Pronouncements, Policy [Policy Text Block] Litigation Case [Axis] Litigation Case [Axis] Non- controlling Interest Noncontrolling Interest [Member] Unsecured Notes Unsecured Debt [Member] Schedule of accrued and other current liabilities Schedule of Accrued Liabilities [Table Text Block] 6.125% Senior Secured Notes due 2027 Senior Secured 6.125% Notes Due February 2027 [Member] Senior Secured 6.125% Notes Due February 2027 Intangible assets Intangible assets, net Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Excluding Goodwill Total long-term debt and other Total long-term debt and other Long-Term Debt Chargebacks Reserve For Chargebacks [Member] Reserve For Chargebacks [Member] Number of business acquisitions Number Of Business Acquisitions Number Of Business Acquisitions Other than Stock options Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract] Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Unrecognized tax benefits Unrecognized Tax Benefits Expenses Costs and Expenses [Abstract] Security Exchange Name Security Exchange Name Weighted-average exercise price (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price International International International Rx [Member] International Rx Purchases of marketable securities Payments to Acquire Marketable Securities Product related research and development Research And Development Expense, Product Related Research And Development Expense, Product Related Senior Secured Credit Facilities Senior Secured Credit Facilities [Member] Senior Secured Credit Facilities [Member] Revenue from Contract with Customer, Segment Benchmark Revenue from Contract with Customer, Segment Benchmark [Member] Maximum shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Interest Interest Payable, Current Segment Information Segment Reporting, Policy [Policy Text Block] Vesting of B+L equity compensation Noncontrolling Interest, Interest, Decrease From Adjustment To Subsidiary Equity Issuance Noncontrolling Interest, Interest, Decrease From Adjustment To Subsidiary Equity Issuance Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Name Outstanding Recovery, Individual Name Proceeds from sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Extinguishment of Debt [Line Items] Extinguishment of Debt [Line Items] Geographical [Domain] Geographical [Domain] Net Carrying Amount Intangible Asset, Excluding Goodwill, Indefinite-Lived Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Litigation and other matters, net of insurance recoveries and restitutions Gain (Loss) from Litigation Settlement Amortization and write-off of debt premiums, discounts and issuance costs Amortization of Debt Issuance Costs and Discounts Stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract] Proceeds from sale of assets and businesses, net of costs to sell Proceeds from Divestiture of Businesses, Net of Cash Divested Ownership percentage by parent Subsidiary, Ownership Percentage, Parent Pension adjustment, net of tax Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Principal Amount Principal amount outstanding Total debt obligations Long-Term Debt, Gross Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Diluted weighted-average common shares (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag Emerging Growth Company Entity Emerging Growth Company Annual amortization rate (as a percent) Debt Instrument, Annual Amortization Rate, Percentage, Period One Debt Instrument, Annual Amortization Rate, Percentage, Period One Underlying Security Market Price Change Underlying Security Market Price Change, Percent Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization The Anticipated Zydus Cabtreo Paragraph IV Proceedings The Anticipated Zydus Cabtreo Paragraph IV Proceedings [Member] The Anticipated Zydus Cabtreo Paragraph IV Proceedings Unfavorable Regulatory Action Unfavorable Regulatory Action [Member] Incremental Term Loan, Maturing in May 2027 Incremental Term Loan, Maturing in May 2027 [Member] Incremental Term Loan, Maturing in May 2027 Other non-current liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] 6.25% Senior Notes Due February 2029 Senior Notes, 6.25%, Due February 2029 [Member] Senior Notes, 6.25%, Due February 2029 Restricted cash Restricted cash Restricted Cash, Current Intangible Asset, Goodwill and Other [Abstract] Intangible Asset, Goodwill and Other [Abstract] Lumify Paragraph I V Proceedings Gland ANDA Litigation Lumify Paragraph I V Proceedings Gland ANDA Litigation [Member] Lumify Paragraph I V Proceedings Gland ANDA Litigation Refinancing Term Facility Due January 2031 Refinancing Term Facility Due January 2031 [Member] Refinancing Term Facility Due January 2031 Restructuring, integration and separation costs Restructuring, integration and separation costs Restructuring Charges And Initial Public Offering Costs Restructuring Charges And Initial Public Offering Costs Gain excluded from hedge effectiveness Derivative, Gain, Excluded Component Derivative, Gain, Excluded Component Product returns Accrued Product Return Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Indefinite-lived Intangible Assets, Major Class Name [Domain] Intangible Asset, Indefinite-Lived, Class [Domain] Diversified Diversified Diversified Segment [Member] Diversified Segment [Member] Litigation Status [Domain] Litigation Status [Domain] All Executive Categories All Executive Categories [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Distribution Fees Reserve For Distribution Fees [Member] Reserve For Distribution Fees [Member] Customary fronting fees (as a percent) Line of Credit Facility, Customary Fronting Fees Percentage Line of Credit Facility, Customary Fronting Fees Percentage Asset Acquisition [Domain] Asset Acquisition [Domain] Omnibus Incentive Plan 2014 And B&L Plan Omnibus Incentive Plan 2014 And B&L Plan [Member] Omnibus Incentive Plan 2014 And B&L Plan Secured leverage ratio Debt Instrument, Covenant Compliance, Secured Leverage Ratio Debt Instrument, Covenant Compliance, Secured Leverage Ratio Schedule of calculation of earnings (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Estimate of possible loss, income tax examination Income Tax Examination, Estimate of Possible Loss SEGMENT INFORMATION Segment Reporting [Text Block] Minimum Minimum [Member] Term Loan B Facility Due February 2027 Term Loan B Facility Due February 2027 [Member] Term Loan B Facility Due February 2027 Liabilities Liabilities [Abstract] Effective income tax rate reconciliation, nondeductible expense, restructuring charges, amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Location, Statement of Income, Balance [Axis] Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Estimated fair value of contingent consideration Business Combination, Consideration Transferred, Liabilities Incurred Business Combination [Line Items] Business Combination [Line Items] Percentage of shares held Sale of Stock, Percentage of Ownership after Transaction Aimee Lenar, Rule Trading Arrangement, Common Stock [Member] Aimee Lenar, Rule Trading Arrangement, Common Stock Finite lived intangible assets, useful life Intangible Asset, Finite-Lived, Useful Life Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Loss) [Line Items] Maximum percentage, present value of cash flows of new debt (as a percent) Debt Instrument, Modification Of Debt, Present Value Of Cash Flows, New Debt, Maximum Threshold Debt Instrument, Modification Of Debt, Present Value Of Cash Flows, New Debt, Maximum Threshold Employee compensation and benefit costs Accrued Employee Benefits, Current Reporting unit, impairment test, estimated cash flows, discount rate Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate Exercise Price Award Exercise Price Restructuring Cost [Table] Restructuring Cost [Table] Recurring basis Fair Value, Recurring [Member] Segment reporting information Segment Reporting [Line Items] Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Components and classification of share-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Percentage of annual excess cash flow (as a percent) Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans. Subsidiary, number of shares transferred, from parent (in shares) Subsidiary, Number Of Shares Transferred, From Parent Subsidiary, Number Of Shares Transferred, From Parent Foreign exchange and other Accounts Receivable, Allowance For Foreign Exchange And Other Accounts Receivable, Allowance For Foreign Exchange And Other Repayments of long-term debt and other financial liabilities Repayments of long-term debt Repayments of Long-Term Debt Unamortized premiums, discounts and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component [Domain] Equity Component [Domain] Measurement Input Type [Domain] Measurement Input Type [Domain] Returns Reserve For Customer Returns [Member] Reserve For Customer Returns [Member] Foreign currency exchange contracts Foreign Exchange Contract [Member] Adoption Date Trading Arrangement Adoption Date Schedule of other expense, net Schedule of Other Nonoperating Income (Expense) [Table Text Block] 126NumberCo 126NumberCo [Member] 126NumberCo Restructuring Type [Axis] Restructuring Type [Axis] B&L Plan B&L Plan [Member] B&L Plan Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Dismissed with Prejudice Dismissed With Prejudice [Member] Dismissed With Prejudice Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Luxembourg Inland Revenue Luxembourg Inland Revenue [Member] Other Proceeds from (Payment for) Other Financing Activity Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Restructuring and Integration Costs Restructuring And Integration Costs [Member] Restructuring And Integration Costs Vision Care, Pharmaceuticals and Surgical Vision Care, Pharmaceuticals, And Surgical [Member] Vision Care, Pharmaceuticals, And Surgical Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Selling, general and administrative Separated-related costs Selling, general and administrative Selling, General and Administrative Expense Type of Restructuring [Domain] Type of Restructuring [Domain] Business Combination [Domain] Business Combination [Domain] Letter of Credit Letter of Credit [Member] Vesting of B+L equity compensation Noncontrolling Interest, Increase from Subsidiary Equity Issuance Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Acquisition-related contingent consideration Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination. RSUs RSUs Restricted Stock Units (RSUs) [Member] 4.875% Senior Notes Due June 2028 Senior Secured 4.875% Notes Due June 2028 [Member] Senior Secured 4.875% Notes Due June 2028 Partner relationships, technology and other Partner Relationships [Member] Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions. All Adjustments to Compensation All Adjustments to Compensation [Member] Corporate Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Business Combination [Axis] Business Combination [Axis] RESEARCH AND DEVELOPMENT Research, Development, and Computer Software Disclosure [Text Block] Net cash provided by operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Revolving Credit Facility Due June 2030 Revolving Credit Facility Due June 2030 [Member] Revolving Credit Facility Due June 2030 Income Statement [Abstract] Income Statement [Abstract] (Deficit) Equity Equity, Attributable to Parent [Abstract] Debt instrument remaining quarterly amortization Debt Instrument, Periodic Payment, Remaining Quarterly Amortization, Period One Debt Instrument, Periodic Payment, Remaining Quarterly Amortization, Period One Document Transition Report Document Transition Report Deferred tax assets, net Deferred Income Tax Assets, Net Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of finite-lived intangible assets Intangible Asset, Finite-Lived [Table Text Block] 8.50% Senior Notes Due January 2027 Senior Notes, 8.50%, Due January 2027 [Member] 8.50% Senior Notes Due January 2027 [Member] Amneal Xifaxan Litigation Amneal Xifaxan Litigation [Member] Amneal Xifaxan Litigation City Area Code City Area Code Troubled Debt Restructuring, Debtor, Type [Domain] Troubled Debt Restructuring, Debtor, Type [Domain] Troubled Debt Restructuring, Debtor, Type [Domain] Fair value of long-term debt Debt Instrument, Fair Value Disclosure Name Forgone Recovery, Individual Name Research and Development [Abstract] Research and Development [Abstract] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity [Domain] Entity [Domain] Shower to Shower Product Liability Litigation Shower To Shower Product Liability Litigation [Member] Shower to Shower Product Liability Litigation [Member] DESCRIPTION OF BUSINESS Nature of Operations [Text Block] Measurement Input, Weighted Average Risk-Adjusted Discount Rate Measurement Input, Weighted-Average Discount Rate [Member] Measurement Input, Weighted-Average Discount Rate [Member] Share-based compensation expense Share-Based Payment Arrangement, Expense Accrued and other current liabilities Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Inventories Business Combination, Recognized Asset Acquired, Inventory, Current Additions Goodwill, Acquired During Period Reporting Unit [Axis] Reporting Unit [Axis] Weighted-average grant date fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Xifaxan Branded Products Xifaxan Branded Products [Member] Xifaxan Branded Products Subsequent Event Type [Domain] Subsequent Event Type [Domain] Total intangible assets Intangible Asset, Excluding Goodwill, after Accumulated Amortization [Abstract] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Payments of financing costs Payments of Debt Issuance Costs Accumulated Other Comprehensive Income Loss [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Current Reporting Status Entity Current Reporting Status Net cash (used in) provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Employee withholding taxes related to share-based awards Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Fixed charge coverage ratio Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio Liabilities: Liabilities, Fair Value Disclosure [Abstract] Schedule of aggregate acquisition consideration Business Combination [Table Text Block] Acquired IPR&D costs Research and Development Expense Redemption price percentage to change in control (as a percent) Debt Instrument, Redemption Price, Percentage, Change in Control Debt Instrument, Redemption Price, Percentage, Change in Control Adjustments to reconcile net (loss) income to net cash provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] 2029 Long-Term Debt, Maturity, Year Three Write-offs charged against the allowance Accounts Receivable, Allowance for Credit Loss, Writeoff Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Term Loan B Facility and Revolving Credit Facility Due 2030 Term Loan B Facility And Revolving Credit Facility Due 2030 [Member] Term Loan B Facility And Revolving Credit Facility Due 2030 Cash Flows From Financing Activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] 5.25% Senior Notes Due February 2031 Senior Notes, 5.25%, Due February 2031 [Member] Senior Notes, 5.25%, Due February 2031 Generics Reporting Unit Generics Reporting Unit [Member] Generics Reporting Unit Foreign currency exchange contracts Derivative Asset INVENTORIES Inventory Disclosure [Text Block] Intangible Asset, Finite-Lived, Class [Axis] Intangible Asset, Finite-Lived, Class [Axis] INTANGIBLE ASSETS AND GOODWILL Intangible Asset and Goodwill [Text Block] Underlying Securities Award Underlying Securities Amount Comprehensive (income) loss attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest REVENUE RECOGNITION Revenue from Contract with Customer [Text Block] Stay of the approval, period Loss Contingency, Stay Of Approval, Period Loss Contingency, Stay Of Approval, Period Term Loan B Facility Due October 2030 Term Loan B Facility Due October 2030 [Member] Term Loan B Facility Due October 2030 [Member] Inventories Increase (Decrease) in Inventories Quarterly amortization payments Debt Instrument, Periodic Payment, Quarterly Amortization Debt Instrument, Periodic Payment, Quarterly Amortization Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table] Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table] Disclosure of the carrying value of amortizable and nonamortizable intangibles assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company. LICENSING AGREEMENTS AND ACQUISITIONS Asset Acquisition, Licensing Agreements, And Divestiture Disclosure [Text Block] Asset Acquisition, Licensing Agreements, And Divestiture Disclosure Segment Reporting [Table] Segment Reporting [Table] Number of shares available for future grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Minimum liquidity Debt Instrument, Covenant, Minimum Liquidity, Amount Debt Instrument, Covenant, Minimum Liquidity, Amount Current portion included in Accrued and other current liabilities Business Combination, Contingent Consideration, Liability, Current Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Balance, beginning of period Balance, end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Current Fiscal Year End Date Current Fiscal Year End Date Revolving Credit Facility Due 2030 Revolving Credit Facility Due 2030 [Member] Revolving Credit Facility Due 2030 Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Alternate term, number of days, after latest maturity date principal amount threshold Debt Instrument, Alternate Term, Number Of Days, After Latest Maturity Date Principal Amount Threshold Debt Instrument, Alternate Term, Number Of Days, After Latest Maturity Date Principal Amount Threshold Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Common shares issued under share-based compensation plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture 5.00% Senior Notes Due February 2029 Senior Notes, 5.00%, Due February 2029 [Member] Senior Notes, 5.00%, Due February 2029 Thereafter Intangible Asset, Finite-Lived, Estimated Amortization Expense, after Year Five Noncontrolling interest distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Three Month Interest Period Three Month Interest Period [Member] Three Month Interest Period Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Measure: Measure [Axis] DURECT Corporation DURECT Corporation [Member] DURECT Corporation Reduction of debt premium Amortization of Debt Discount (Premium) Exchange Offer Exchange Offer [Member] Exchange Offer Redemption price percentage to change in control (as a percent) Debt Instrument, Redemption Price, Percentage, Change In Control Debt Instrument, Redemption Price, Percentage, Change In Control 7.00% Senior Notes Due January 2028 Senior Notes, 7.00%, Due January 2028 [Member] Senior Notes 7.00 Percent Due January 2028 [Member] Interest settlements from cross-currency swaps Receipts in interest settlement of cross-currency swaps Payments for (Proceeds from) Hedge, Investing Activities Equity Components [Axis] Equity Components [Axis] Valuation allowance against deferred tax assets Deferred Tax Assets, Valuation Allowance Entity Interactive Data Current Entity Interactive Data Current Variable Rate [Axis] Variable Rate [Axis] Net (income) loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Revolving Credit Facility Due April 2030 Revolving Credit Facility Due April 2030 [Member] Revolving Credit Facility Due June 2030 [Member] Smaller Reporting Company Entity Small Business Comprehensive income (loss) attributable to Bausch Health Companies Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Aimee Lenar, Trading Arrangement, Vesting and Settlement [Member] Aimee Lenar, Trading Arrangement, Vesting and Settlement Sun Pharmaceuticals, Inc. Sun Pharmaceuticals, Inc. [Member] Sun Pharmaceuticals, Inc. Estimated useful life of acquired intangible assets Intangible Asset, Finite-Lived, Acquired, Weighted-Average Amortization Period Payments/Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other non-current assets Other Assets, Noncurrent Document Type Document Type Repurchased debt, aggregate principal amount Debt Instrument, Repurchased Face Amount Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Gain (loss) on extinguishment of debt Loss (gain) on extinguishment of debt Gain (loss) on extinguishment of debt Gain (Loss) on Extinguishment of Debt Schedule of indefinite-lived intangible assets Intangible Asset, Indefinite-Lived [Table Text Block] SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Expensed upfront payment of acquired IPR&D costs Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff 2027 Revolving Credit Facility Revolving Credit Facility Due February 2027 [Member] Revolving Credit Facility Due February 2027 Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Issuance of long-term debt, net of discounts Proceeds from Issuance of Long-Term Debt Local Phone Number Local Phone Number CANADA CANADA Work in process Inventory, Work in Process, Gross Net Investment Hedging Net Investment Hedging [Member] Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Commitments and contingencies (Note 17) Commitments and Contingencies Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] 2030 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four Executive Category: Executive Category [Axis] Amortization of inventory step-up resulting from acquisitions Amortization, Interim Contract And Inventory Step From Acquisition Amortization, Interim Contract And Inventory Step From Acquisition Schedule of variable consideration provisions Summary Of Valuation And Qualifying Accounts [Table Text Block] Summary Of Valuation And Qualifying Accounts [Table Text Block] Inventories, net Inventory, Net Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Goodwill impairments Goodwill impairments Goodwill impairments Goodwill, Impairment Loss, Not Included In Asset Impairment Charges Goodwill, Impairment Loss, Not Included In Asset Impairment Charges Percentage of cash proceeds from incurrence of debt (as a percent) Line Of Credit Facility, Percentage Of Net Proceeds From Incurrence Of Debt Payable As Mandatory Pre-payments Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments. PEO Name PEO Name Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Fair value, contingent consideration obligations, discount rate Business Combination, Contingent Consideration, Liability, Measurement Input Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Product Concentration Risk Product Concentration Risk [Member] Solta Medical Solta Medical Solta Medical Segment [Member] Solta Medical Segment Xifaxan Antitrust Litigation Xifaxan Antitrust Litigation [Member] Xifaxan Antitrust Litigation Other Other Accrued Liabilities, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Base Rate Base Rate [Member] Rebates, Advertising Credits Portion Reserve For Rebates, Advertising Credits Portion [Member] Reserve For Rebates, Advertising Credits Portion [Member] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Debt Instrument [Axis] Debt Instrument [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Share-based compensation arrangement by share-based payment award, purchase price of common stock, percent Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Tax Period [Axis] Tax Period [Axis] Violation of Canadian Provincial Securities Legislation Violation of Canadian Provincial Securities Legislation [Member] Violation of Canadian Provincial Securities Legislation [Member] Schedule of assets and liabilities associated with derivatives, included in the consolidated balance sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share) Earnings Per Share, Basic Measurement Input Type [Axis] Measurement Input Type [Axis] Term Loan B Facility Due September 2028 Term Loan B Facility Due September 2028 [Member] Term Loan B Facility Due September 2028 Total current assets Assets, Current Insider Trading Arrangements [Line Items] Non-current portion of long-term debt Non-current portion of long-term debt Long-Term Debt, Excluding Current Maturities Allowances for losses on trade receivable and inventories Allowances for Losses on Accounts Receivable and Inventories Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions. Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Contingent consideration, liability Business Combination, Contingent Consideration, Liability Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Senior Secured 11.00% Notes, First Lien, Due June 2028 Senior Secured 11.00% Notes, First Lien, Due June 2028 [Member] Senior Secured 11.00% Notes, First Lien, Due June 2028 Concentration risk percentage Concentration Risk, Percentage Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer [Member] Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer 9.00% Senior Unsecured Notes due 2025 Senior Notes, 9.00%, Due December 2025 [Member] 9.00% Senior Notes due December 2025 [Member] Equity Awards Adjustments Equity Awards Adjustments [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] Plan Name [Axis] Plan Name [Axis] Schedule of activity in allowance for credit losses Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Income Tax Authority [Domain] Income Tax Jurisdiction [Domain] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Finite-lived intangible assets: Intangible Asset, Finite-Lived, after Accumulated Amortization [Abstract] Schedule of the components and classification of share-based compensation expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] 2031 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Five Bausch Health Companies Inc. Shareholders’ Deficit Parent [Member] Entity Address, Country Entity Address, Country 8.375% Senior Notes Due October 2028 Senior Secured 8.375% Notes Due October 2028 [Member] Senior Secured 8.375% Notes Due October 2028 Trade receivables, net Receivables, Net, Current Term Loan B Due January 2031 Term Loan B Due January 2031 [Member] Term Loan B Due January 2031 Number of lawsuits pending Loss Contingency, Pending Claims, Number Hedging Designation [Domain] Hedging Designation [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Income Tax Authority [Axis] Income Tax Jurisdiction [Axis] Acquisitions and other investments Payments To Acquire Businesses And For Other Investments Payments To Acquire Businesses And For Other Investments INCOME TAXES Income Tax Disclosure [Text Block] 2014 Plan Omnibus Incentive Plan 2014 [Member] Omnibus Incentive Plan 2014 [Member] Accounts payable Accounts Payable, Current Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Percentage of net cash proceeds of pro rata basis with obligations (as a percent) Line of Credit Facility, Percentage of Net Cash Proceeds Of Pro Rata Basis With Obligations Line of Credit Facility, Percentage of Net Cash Proceeds Of Pro Rata Basis With Obligations Debt Instrument, Period [Axis] Debt Instrument, Period [Axis] Debt Instrument, Period Aggregate purchase consideration Aggregate purchase consideration Business Combination, Consideration Transferred Entity Filer Category Entity Filer Category Cross-currency swaps Currency Swap [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Lumify Paragraph I V Proceedings Somerset ANDA Litigation Lumify Paragraph I V Proceedings Somerset ANDA Litigation [Member] Lumify Paragraph I V Proceedings Somerset ANDA Litigation SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Rebates Reserve For Rebates [Member] Reserve For Rebates [Member] Term Loan B Facility Due January 2031 Term Loan B Facility Due January 2031 [Member] Term Loan B Facility Due January 2031 Net income (loss) Net income (loss) Net (loss) income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Current assets: Assets, Current [Abstract] Net fair value Derivative Liability Entity Address, Address Line One Entity Address, Address Line One Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Excluded from computation of earnings per share, performance conditions not met (in shares) Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Principles of Consolidation Consolidation, Policy [Policy Text Block] Estimated fair value of contingent consideration Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount Research and development Research and development Research and development Research and Development Expense (Excluding Acquired in Process Cost) 11.00% First Lien Senior Notes, Due September 2028 Senior Secured 11.00% Notes, First Lien, Due September 2028 [Member] Senior Secured 11.00% Notes, First Lien, Due September 2028 Statement [Table] Statement [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Interest income Investment Income, Interest Prepaid expenses and other current assets Prepaid expenses and other current assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Legal matters and related fees Legal settlements and Related Fees Legal settlements and Related Fees Valeant US Securities Litigation, Opt-Out Action Valeant US Securities Litigation, Opt-Out Action [Member] Valeant US Securities Litigation, Opt-Out Action Asset acquisition, consideration transferred, transaction cost Asset Acquisition, Consideration Transferred, Transaction Cost Stock Options and RSUs Share-Based Payment Arrangement [Member] Damages sought Loss Contingency, Damages Sought, Value